BrainSignsLab - NPTX2 in Cerebrospinal Fluid Predicts the Progression

Journal article

Anja Soldan, Sungtaek Oh, Taekyung Ryu, C. Pettigrew, Yuxin Zhu, A. Moghekar, Mei-Fang Xiao, G. Pontone, M. Albert, C. Na, P. Worley
Annals of Neurology, 2023

Semantic Scholar DOI PubMed

Cite

APA Click to copy
Soldan, A., Oh, S., Ryu, T., Pettigrew, C., Zhu, Y., Moghekar, A., … Worley, P. (2023). NPTX2 in Cerebrospinal Fluid Predicts the Progression From Normal Cognition to Mild Cognitive Impairment. Annals of Neurology.

Chicago/Turabian Click to copy
Soldan, Anja, Sungtaek Oh, Taekyung Ryu, C. Pettigrew, Yuxin Zhu, A. Moghekar, Mei-Fang Xiao, et al. “NPTX2 In Cerebrospinal Fluid Predicts the Progression From Normal Cognition to Mild Cognitive Impairment.” Annals of Neurology (2023).

MLA Click to copy
Soldan, Anja, et al. “NPTX2 In Cerebrospinal Fluid Predicts the Progression From Normal Cognition to Mild Cognitive Impairment.” Annals of Neurology, 2023.

BibTeX Click to copy

@article{anja2023a,
  title = {NPTX2 in Cerebrospinal Fluid Predicts the Progression From Normal Cognition to Mild Cognitive Impairment},
  year = {2023},
  journal = {Annals of Neurology},
  author = {Soldan, Anja and Oh, Sungtaek and Ryu, Taekyung and Pettigrew, C. and Zhu, Yuxin and Moghekar, A. and Xiao, Mei-Fang and Pontone, G. and Albert, M. and Na, C. and Worley, P.}
}

Abstract

This study examined whether cerebrospinal fluid (CSF) baseline levels of the synaptic protein NPTX2 predict time to onset of symptoms of mild cognitive impairment (MCI), both alone and when accounting for traditional CSF Alzheimer's disease (AD) biomarker levels. Longitudinal NPTX2 levels were also examined.